PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-313.81%
Both yoy net incomes decline, with AVXL at -1867.11%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
289.12%
SBC growth of 289.12% while AVXL is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
-122.10%
Both reduce yoy usage, with AVXL at -66.02%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
113.90%
AP growth of 113.90% while AVXL is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-180.39%
Both reduce yoy usage, with AVXL at -857.49%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
2618.61%
Lower 'other non-cash' growth vs. AVXL's 39632.85%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
17.02%
Some CFO growth while AVXL is negative at -1405.15%. John Neff would note a short-term liquidity lead over the competitor.
-23.76%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.76%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-278.89%
We cut debt repayment yoy while AVXL is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.